Merck & Co. Inc. and AstraZeneca PLC have agreed to work together for another two years after extending a nearly 30-year joint venture that would have otherwise ended in September. The companies announced an agreement to extend their longstanding partnership June 27 after coming to terms that could benefit both parties.
The partnership is centered around the acid reflux drugs Nexium (esomeprazole), which is expected to post dwindling sales once losing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?